Small Lymphocytic Lymphoma (SLL) | Tumor

CURE’s small lymphocytic lymphoma (SLL) page is a go-to resource for oncology news and updates in the world of SLL. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in small lymphocytic lymphoma (SLL).

FDA Approves Calquence for Leukemia and Lymphoma Subsets

November 21st 2019

In partnership with the Australian Therapeutic Goods Administration (TGA) and Health Canada, the Food and Drug Administration (FDA) has granted supplemental approval to Calquence (acalabrutinib) for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

FDA Approves Venclexta-Gazyva Combo as Frontline Treatment for CLL/SLL

May 15th 2019

The Food and Drug Administration has approved the combination use of Venclexta plus Gazyva for the frontline treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

2018 FDA Advancements in Small Lymphocytic Leukemia

November 29th 2018

Take a look at the FDA’s decisions for the treatment of SLL that happened this year.

Imbruvica Yields Favorable Safety Outcomes in Two Types of Lymphomas

November 12th 2018

Imbruvica (ibrutinib) is a safe treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL), according to a pooled analysis of four clinical trials.

FDA Approves Copiktra for Two Types of Blood Cancer

September 25th 2018

The drug was approved for adults with chronic lymphocytic leukemia and small lymphocytic lymphoma. And was granted an accelerated approval for follicular lymphoma.